Navigation Links
Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin
Date:3/31/2015

Cleveland, OH (PRWEB) March 31, 2015

Diasome Pharmaceuticals, Inc. (http://www.diasome.com) has received notice from its licensor, SDG, Inc., that a United States patent has recently been allowed for the Company’s technology for liver-targeted insulin therapy.

Entitled “Lipid Construct for Delivery of Insulin to a Mammal,” this patent covers composition of matter claims related to the use of Diasome’s proprietary Hepatocyte Directed Vesicles (“HDV”) as a system for enabling injected insulin to more effectively reach the liver’s metabolic cells, called hepatocytes.

“While all naturally secreted insulin is first and primarily used by the liver as a signal to store sugar from the food we eat, injected insulin therapy has been shown to have great difficulty in successfully reaching the liver in patients with diabetes,” said W. Blair Geho, MD, PhD, Diasome’s Chief Scientific Officer. “The HDV system has been designed as a potentially first-in-class additive to approved insulin therapies and has been shown in Phase 2 human testing to have a significant and positive impact on controlling blood sugar levels in patients.”

Diasome’s most advanced clinical-stage therapy is an injected form of pre-meal insulin that incorporates the HDV nanotechnology system. This product has been enabled for Phase 3 testing by the US FDA.

About Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.

Read the full story at http://www.prweb.com/releases/2015/03/prweb12613561.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Diasome Pharmaceuticals, Inc. Announces Issuance of Oral Insulin Patent by the US PTO
2. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
3. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
4. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
7. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
8. Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
9. PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website
10. Synthetic Biology Market by Tool, Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & Sequencing), Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to 2018
11. PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2019)... ... , ... ARPR , an award-winning tech PR agency at the epicenter of the future ... Agency of the Year in the Ragan’s Health Care PR & Marketing Awards. This award ... firm also revealed today that its healthIT practice group grew by 18 percent in Q3 ...
(Date:10/10/2019)... , ... October 10, 2019 , ... ... the largest network of clinical research centers in Europe. All Pratia research centers ... in Europe to become trained and certified as Virtual Trial Capable and prepared ...
(Date:10/3/2019)... ... 2019 , ... Today Cereset®, the only proven non-invasive technology ... its randomized research trial for individuals with persisting symptoms following mild-Traumatic Brain Injury ... non-invasive technology which compares tones delivered to a subject’s brain guided by the ...
(Date:10/3/2019)... ... ... eKare’s inSight® digital 3D imaging and wound measurement system has been selected to ... Science Network (EMAHSN), the innovation arm of the NHS. The program was designed to ... deploy solutions to the most pressing challenges facing the NHS. , The Digital ...
Breaking Biology Technology:
(Date:9/30/2019)... ... ... As human induced pluripotent stem cells (hiPSCs) move closer to becoming a possible ... human heart, there is an increasing need for stable stem cell lines that allow ... easily recorded. A study released today in STEM CELLS details the development of one ...
(Date:9/25/2019)... ... September 25, 2019 , ... LeadingBiotech , an exclusive ... announces its inaugural South CEO conference to be held on October ... by Tulane University, this invitation-only meeting convenes biopharma executives to discuss pressing issues ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... that it has received 300 five-star reviews on the popular travel review site, ... experience,” “amazing views and incredible food” and “unique local experience.” These sentiments have ...
Breaking Biology News(10 mins):